The Technical Analyst
Deciphera Pharmaceuticals [DCPH]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Deciphera Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.69% $10.69
Last updated: 16 May 2022 @ 10:51 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 707.85 mill |
| EPS: | -5.16 |
| P/E: | 0.000 |
| Earnings Date: | Aug 01, 2022 |
| SharesOutstanding: | 66.22 mill |
| Avg Daily Volume: | 1.333 mill |
| RATING 2022-05-13 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$12.25 (14.60%) $1.561 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.787 ( +/- 7.63%) Range: 9.52 - 11.10 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-04-29 | Brightstar Associates Llc | Buy | 3 389 830 | Warrants (right to buy) |
| 2022-04-29 | Brightstar Associates Llc | Buy | 1 478 978 | Common Stock |
| 2022-03-21 | Hoerter Steven L. | Sell | 3 150 | Common Stock |
| 2022-02-16 | Pitman Jama | Sell | 1 146 | Common Stock |
| 2022-02-16 | Kelly Thomas Patrick | Sell | 1 368 | Common Stock |
| INSIDER POWER |
|---|
| 82.31 |
| Last 100 transactions |
| Buy: 6 408 857 | Sell: 782 611 |
Forecast:
12:30 - $10.71
Live Trading Signals (every 1 min)
Forecast
1: 11:00 - $10.67
Forecast 2: 11:50 - $10.81
Forecast 3: 12:30 - $10.71
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.69 (3.69% ) |
| Volume | 0.108 mill |
| Avg. Vol. | 1.333 mill |
| % of Avg. Vol | 8.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DCPH
320 Signals | Accuracy: 21.56% | Accuracy Buy: 23.75% | Accuracy Sell: 19.38%
Avg return buy: -0.08 % | Avg return sell: 0.11 %
$1 invested is now $0.87 or -12.60% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 10:42 | sell | $10.68 | $10.70 @ May 16 - 10:49 | 0.23% |
|---|---|---|---|---|
| May 16 - 10:38 | buy | $10.70 | $10.68 @ May 16 - 10:40 | -0.19% |
| May 16 - 10:37 | sell | $10.69 | $10.70 @ May 16 - 10:38 | 0.09% |
| May 16 - 10:04 | buy | $10.33 | $10.68 @ May 16 - 10:35 | 3.39% |
| May 16 - 09:31 | sell | $10.24 | $10.33 @ May 16 - 10:03 | 0.88% |
| May 13 - 15:55 | buy | $10.29 | $10.24 @ May 16 - 09:30 | -0.49% |
| May 13 - 15:35 | sell | $10.30 | $10.29 @ May 13 - 15:55 | -0.10% |
| May 13 - 15:03 | buy | $10.28 | $10.30 @ May 13 - 15:35 | 0.19% |
| May 13 - 13:56 | sell | $10.31 | $10.28 @ May 13 - 15:02 | -0.29% |
| May 13 - 13:24 | buy | $10.24 | $10.29 @ May 13 - 13:52 | 0.49% |
DCPH
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. Its lead drug candidate is ripretinib for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. The company is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase Ib/II trial to treat solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, its preclinical stage drug candidate is DCC-3116 for the treatment of RAS mutant cancers. Deciphera has partnership with K2fly, which offers cloud monitoring platform, to create an integrated monitoring and governance platform for tailing storage facilities. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2022-05-04 07:00:00 - Press Release
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq:dcph) today announced financial results for the first quarter ended march 31, 2022, and provided a corporate update. “we have made significant progress on our 2022 goals so far this year, demonstrating our commercial success with qinlock®, strengthening our balance sheet, and rapidly advancing our potential best-in-class and first-in-class clinical-stage pipeline,” said steve hoerter, president and chief executive officer
2022-04-29 16:05:00 - Press Release
Deciphera Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Pre-funded Warrants And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,501,239 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 9,748,761 shares of its common stock at an exercise price of $0.01 per share. the share
2022-04-27 00:02:00 - Press Release
Deciphera Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock And Pre-funded Warrants
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 5,251,239 shares of its common stock at a public offering price of $10.00 per share. in addition, in lieu of common stock to certain investors, deciphera is offering pre-funded warrants to purchase 9,
2022-04-12 15:50:00 - Press Release
Deciphera Pharmaceuticals Presents Preclinical Data From Dcc-3116 Program At The Aacr Annual Meeting
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of preclinical data for dcc-3116, the company's first-in-class ulk kinase inhibitor, in combination with krasg12c inhibitors in non-small cell lung cancer (nsclc) models at the american association for cancer research (aacr) annual meeting 2022 in new orleans, louisiana
2022-01-24 17:00:00 - Press Release
Deciphera Pharmaceuticals Presents Results From The Intrigue Phase 3 Clinical Study At The American Society Of Clinical Oncology Plenary Series Session
Waltham, mass.--(business wire)--deciphera pharmaceuticals, inc. (nasdaq: dcph), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, announced the presentation of results from the intrigue phase 3 study of qinlock (ripretinib) in patients with gastrointestinal stromal tumor (gist) previously treated with imatinib at the american society of clinical oncology (asco) plenary series session. the presentation, which follows the ann
Latest News
2022-05-08 05:22:06 - Seeking Alpha
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2022 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Margarida Duarte - SVP & Head, International Steven Hoerter - President, CEO & Director Daniel Martin - SVP & Chief Commercial Officer Matthew Sherman - EVP & Chief Medical Officer Thomas Kelly - EVP, CFO & Treasurer Conference Call Participants Daniel Wolle - JPMorgan Chase & Co. Eun Yang - Jefferies Allison Bratzel - Piper Sandler & Co. Paul Jeng - Guggenheim Securities Reni Benjamin - JMP Securities Andrew Berens - SVB Leerink Peter Lawson - Barclays Bank Bradley Canino - Stifel, Nicolaus & Company Maghan Meyers - SVP, Argot Partners Operator Good morning, everyone, and welcome to Deciphera Pharmaceuticals First Quarter 2022 Financial Results Conference Call...
2022-05-06 12:02:07 - Zacks Investment Research
Deciphera (DCPH) Down Despite Narrower-Than-Expected Q1 Loss
Deciphera (DCPH) reports narrower-than-expected loss in the first quarter of 2022 while revenues beat estimates.
2022-05-04 09:47:19 - Zacks Investment Research
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-04-27 07:55:03 - Benzinga
Deciphera Raises $150M Via Equity Offering
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) has priced an underwritten public offering of 5.25 million shares at $10.00 per share, for gross proceeds of $150 million. The offer price represents a discount of 3.5% from the last close price of $10.36 on Tuesday.
2022-04-22 13:32:25 - Zacks Investment Research
4 Reasons to Add Deciphera (DCPH) Stock to Your Portfolio
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since approval. The recent restructuring initiative is saving costs.
2022-04-21 11:19:17 - Zacks Investment Research
J&J Sets in Motion Drug/Biotech Q1 Earnings: 3 Stocks to Buy
Investors typically look at J&J's (JNJ) results to gauge how the rest of the drug sector will fare.
2022-04-15 11:17:07 - Zacks Investment Research
Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 73%: Read This Before Placing a Bet
The mean of analysts' price targets for Deciphera Pharmaceuticals, Inc. (DCPH) points to a 73.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2022-02-09 13:49:24 - Zacks Investment Research
Deciphera (DCPH) Q4 Loss Wider Than Expected, Revenues Beat
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
2022-02-08 21:52:04 - Seeking Alpha
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call Transcript
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q4 2021 Results - Earnings Call Transcript
2022-02-08 18:28:14 - Zacks Investment Research
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?